Table 2 Characteristics of SR-aGVHD on the time of enrollment
Characteristics of aGVHD | Total (n = 130) | MSC group (n = 65) | Control group (n = 65) | P |
|---|---|---|---|---|
Severity of aGVHD, n (%) | Â | Â | Â | 0.921 |
 Grade II | 63 (48.5%) | 32 (49.2%) | 31 (47.7%) |  |
 Grade III | 34 (26.1%) | 16 (24.6%) | 18 (27.7%) |  |
 Grade IV | 33 (25.4%) | 17 (26.2%) | 16 (24.6%) |  |
Site of aGVHD, n (%) | ||||
 Skin | 106 (81.5%) | 55 (84.6%) | 53 (81.5%) | 0.64 |
 GI | 90 (69.2%) | 42 (70.8%) | 48 (73.8%) | 0.254 |
 Liver | 32 (24.6%) | 15 (23.1%) | 17 (26.2%) | 0.684 |
Number of sites, n (%) | Â | Â | Â | 0.888 |
 1 | 56 (43.1%) | 28 (53.1%) | 28 (53.1%) |  |
 2 | 48 (36.9%) | 25 (38.5%) | 23 (35.4%) |  |
 3 | 26 (20.0%) | 12 (18.5%) | 14 (21.5%) |  |